SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, and Pfizer Inc. (NYSE: PFE) today announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E (eIF4E), a key oncogenic driver located downstream from both the RAS and PI3K signaling pathways. eIF4E is an effector protein that

Company Raises $145 Million in Eighteen Months to Complete Development and Early Commercialization of Breakthrough DNA Sequencing Platform SAN DIEGO—January 9, 2020 – Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, today announced it has raised an additional $60 million with the completion of its Series C financing. The funding round was led by Madrone Capital Partners. Current investors include ARCH Ven

Indigo raises an additional $200M, comprised of $175M in convertible equity and $25M in debt, bringing its total capital raised to approximately $850M. Since its last financing round in September 2018, Indigo has launched and expanded its key business lines–including Indigo Grain Marketplace, Indigo Carbon, and Indigo Transport–to de-commoditize agriculture. The new capital will support the continued global development of Indigo Grain Marketplace, an ecommerce platform for di